SecBot SecBot
Biotech Drug Report Generated Oct 31, 2026

Alprolix

SNY·Sanofi
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed since 2014.
Why 3/10
Alprolix is an already-approved, marketed drug with no pending regulatory decision or pivotal readout in the next 12 months. It is a mature product within Sanofi's large, diversified portfolio, so no single binary catalyst exists to drive a significant share-price move for SNY.
Actionable Insight NEUTRAL

Alprolix has no upcoming binary catalysts (PDUFA dates or pivotal readouts) as an already-approved, marketed drug. The next event to watch is any Sanofi quarterly earnings disclosure of rare-blood-disorders segment revenue, which would show whether Alprolix is holding share against Idelvion and newer non-factor competitors. The key long-term overhang is the projected July 2028 loss of exclusivity, which could open the door to biosimilar competition.

Price Chart

Loading chart...

Executive Summary

Alprolix (eftrenonacog alfa) is an FDA-approved recombinant Factor IX Fc fusion protein for hemophilia B, first approved in 2014 and now marketed by Sanofi (ticker: SNY) following its $11.6 billion acquisition of Bioverativ in 2018. It was the first extended half-life factor IX therapy and has over a decade of clinical experience with more than 1,400 patients treated. For Sanofi investors, Alprolix is a mature, cash-flowing product within a much larger rare-blood-disorders portfolio that also includes the faster-growing Altuviiio (hemophilia A) and Qfitlia. The drug faces growing competition from Idelvion (CSL Behring), Hemgenix gene therapy, and newer non-factor therapies, with projected loss of exclusivity around July 2028.

How It Works

Alprolix is a replacement therapy for people with hemophilia B, a genetic bleeding disorder where the body lacks enough clotting factor IX. The drug is a lab-made version of factor IX fused to an Fc protein (an antibody fragment) that keeps it in the bloodstream longer, meaning patients need fewer intravenous infusions compared to standard factor IX products. It helps blood clot normally to prevent or stop bleeding episodes.

Trial Status

Alprolix was approved by the FDA on March 28, 2014, based on Phase 3 studies including the B-LONG trial in adults/adolescents and the Kids B-LONG trial in pediatric patients. It is now a commercially marketed product with over 10 years of real-world experience. Real-world evidence and new analyses continue to be presented at medical conferences such as ISTH.

The Two-Sided Case

▲ Bull Case4
First-to-market extended half-life factor IX therapy with over 10 years of real-world data and established physician trust.
Room temperature storage stability (up to 6 months at ≤30°C) adds patient convenience and competitive differentiation.
Part of Sanofi's broader rare-blood-disorders franchise, benefiting from cross-selling and integrated patient support services.
Hemophilia B is a lifelong condition requiring chronic therapy, providing a stable recurring revenue base.
▼ Bear Case5
Faces direct competition from Idelvion (CSL Behring), another extended half-life factor IX product with 14-day dosing.
Gene therapy Hemgenix (CSL Behring) offers a one-time curative option for eligible adults, potentially shrinking the addressable patient pool.
Newer non-factor therapies (Sanofi's own Qfitlia, Pfizer's Hympavzi, Novo Nordisk's Alhemo) provide subcutaneous injection alternatives.
Projected loss of exclusivity around July 2028 opens the door to biosimilar competition, pressuring pricing and market share.
Alprolix is a small part of Sanofi's overall business (Sanofi had ~€46B+ annual revenue), so even strong performance has limited impact on SNY stock.

Upcoming Catalysts

  • No upcoming binary catalysts (PDUFA, pivotal readout) for Alprolix as an already-approved product.
  • Sanofi quarterly earnings reports will disclose rare-blood-disorders segment performance.
  • Potential biosimilar entry risk around projected July 2028 loss of exclusivity.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Sanofi 6-K SNY ·Originating report

Sources · 11

Hover a chip for the title
1 fda.gov2 drugs.com3 sanofi.com4 drugpatentwatch.com5 cliffbio.com6 sanofi.us7 alprolix.com8 pro.campus.sanofi9 sobi.com10 koreabiomed.com11 investors.biogen.com